Fabry-Experte in Ostschweiz

Prof. Dr. med. Pierre-Alexandre Krayenbühl, eMBA HSG

Facharzt FMH Allgemeine Innere Medizin
Spezialsprechstunde für Eisenstoffwechsel und seltene Erkrankungen
Lehr- und Forschungstätigkeit am UniversitätsSpital Zürich
Brauereistrasse 3, 8610 Uster
Tel.: +41 (0)44 806 32 22
Email: Pierre-Alexandre.Krayenbuehl@sffd.ch

Schulen, Studium, Diplome

1977 – 1983 Primary school Witikon (Zürich), Gockhausen (Dübendorf)
1983 – 1989 Gymnasium Typus B und Matura an der Kantonschule Rämibühl Zürich
1991 – 1996 Studium, Human medicine, Faculty of Medicine, University of Zurich
1996 State examination (Staatsexamen), Faculty of Medicine, University of Zurich


1997 – 1998 Assistant physician, Departement of Surgery, University Hospital Zurich
1998 – 2000 Assistant physician, Department of Medicine, Waid City Hospital, Zurich
2000 – 2003 Assistant physician, Division of Internal Medicine, University Hospital Zurich
2003 – 2014 Senior physician, Division of Internal Medicine, University Hospital Zurich
2003 – current Lecturer at the Medical Faculty University of Zurich
2008 – current Accredited examiner federal state examination for internal medicine
2014 – 2021 Chief Physician, Clinic for Internal Medicine Hospital Linth
2021 – current Family practice

Mitgliedschaften und Teilnahmen an Boards

  • Swiss Society of General Internal Medicine (SGIM)
  • Zurich Association of Physicians (AerzteGesellschaft des Kantons Zürich, AGZ)
  • International BioIron Society (IBS)
  • Fabrysuisse
  • Swiss Foundation of Fabry Disease (SFFD)
  • Member of the Fabry Outcomes Survey (FOS) executive committee
  • Northern European Fabry / Gaucher Diseases Advisory Board
  • Advisory Board Takeda Pharma AG
  • Editorial Board: Leading Opinion Innere Medizin

Wissenschaftliche Kooperationen

  • Institute for Biomedical Engineering, Division of Biomaging / MR spectroscopy ETH Zürich
  • Functional Genomics Center Zürich (ETH-Universität Zürich)
  • Institute of food, nutrition and health ETH Zurich
  • Centre de Transplantation, Centre hospitalier universitaire vaudois (CHUV), Lausanne
  • Exercise Physiology, ETH Zurich
  • National University of Singapore


  • Hemmi-Preis 2011, dotiert mit 20’000 CHF, für die Arbeit: „Intravenous iron for the treatment of fatigue in non-anemic, premenopasual women with low serum ferritin concentration“ (Blood 2011; 118(12):3222-7).

Schweizerischer Nationalfonds

  • Nationalfonds Projekt 320030_144172: „Development of a new assay for the quantification of humen serum hepcidin and its implementation in patients with iron related disorders“ (2012-2014).

Tätigkeit als Reviewer

  • Lancet, European Journal of Pediatrics, Plos one, GUT, Annals of Hematology, Swiss Medical Weekly Praxis


  • German
  • French
  • English


Peer-reviewed articles

  1. Krayenbuehl PA, Wiesli P, Maly FE, Vetter W, Schulthess G. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. Atherosclerosis 2005;179:103-10. Impact factor: 4.09 (2010)
  2. Krayenbuehl PA, Walczyk T, Schoenberg R, von Blanckenburg F, Schulthess G. Hereditary hemochromatosis is reflected in the iron isotope composition of blood. Blood 2005;105:3812-6. Impact factor: 10.56 (2010)
  3. Krayenbuehl PA, Maly FE, Hersberger M, Wiesli P, Himmelmann A, Eid K, Greminger P, Vetter W, Schulthess G. Tumor necrosis factor-alpha -308G>A allelic variant modulates iron accumulation in patients with hereditary hemochromatosis. Clin Chem 2006;52:1552-8. Impact factor: 6.89 (2010)
  4. Schulthess G, Wiesli P, Krayenbuehl PA. Chlamydia pneumoniae, harmful only for peripheral arteries? Int J Cardiol 2006;112:249-50 (original research results presented in a letter to the editor). Impact factor: 6.80 (2010)
  5. Wiesli P, Lehmann R, Krayenbuehl PA, Schmid C, Spinas GA. Assessment of Basal Insulin Requirement Using Fasting Tests in Insulin-treated Patients with Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes 2006;114:539-43. Impact factor: 1.83 (2010)
  6. Schmid C, Zwimpfer C, Brandle M, Krayenbuehl PA, Zapf J, Wiesli P. Effect of thyroxine replacement on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism. Clin Endocrinol 2006;65:706-11. Impact factor: 3.32 (2010)
  7. Krayenbuehl PA, Wiesli P, Schmid M, Schmid C, Ehses JA, Hersberger M, Vetter W, Schulthess G. TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp Clin Endocrinol Diabetes 2007;115:322-6. Impact factor: 1.82 (2010)
  8. Wiesli P, Krayenbuehl PA, Kerwer O, Seifert B, Schmid C. Maintenance of glucose control in patients with type 1 diabetes during acute mental stress by riding high-speed rollercoasters. Diabetes Care 2007;30:1599-601. Impact factor: 7.14 (2010)
  9. Schmid C*, Krayenbuehl PA *, Bernays RL, Zwimpfer C, Maly FE, Wiesli P. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin Chem 2007;53:1484-8. (*equal contribution). Impact factor: 6.89 (2010)
  10. Krayenbuehl PA, Wiesli P, Schmid C, Lehmann R, Spinas G, Berneis K. Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size. Swiss Med Wkly 2008;138:275-80. Impact factor: 1.82 (2010)
  11. Rizzo M, Krayenbuehl P, Pernice V, Frasheri A, Battista Rini G, Berneis K. LDL size and subclasses in patients with abdominal aortic aneurysm. Int J Cardiol 2009;134:406-8. Impact factor: 6.80 (2010)
  12. Wiesli P, Krayenbuehl P, Uthoff H, Seifert B, Schmid C. Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes. Diabetologia 2009;52:1816-9. Impact factor: 6.98 (2010)
  13. Krayenbuehl PA, Hersberger M, Truninger K, Müllhaupt B, Maly FE, Bargetzi M, Schulthess G. Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. Eur J Gastroenterol Hepatol 2010;22:835-41. Impact factor: 1.60 (2010)
  14. Schwarz P, Strnad P, von Figura G, Janetzko A, Krayenbuehl PA, Adler G, Kulaksiz H. A novel monoclonal antibody immunoassay for the detection of human serum hepcidin. J Gastroenterol 2011;46(5):648-56. Impact factor: 3.61 (2010)
  15. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in non-anemic, premenopausal women with low serum ferritin concentration. Blood 2011;118(12):3222-7. Impact factor: 10.56 (2010)
  16. Hotz K, Krayenbuehl PA, Walczyk T. Mobilization of storage iron is reflected in the iron isotopic composition of blood in humans. J Biol Inorg Chem 2012;17(2):301-9. Impact factor: 3.28 (2010)
  17. Trieß C, von Figura G, Stuhrmann M, Butzeck B, Krayenbuehl PA, Strnad P, Kulaksiz H. Diagnosis of hereditary hemochromatosis in the era of genetic testing. Dig Dis Sci. 2012; 57(11):2988-94. Impact factor: 2.11 (2011)
  18. Goetze O, Schmitt J, Spliethoff K, Theurl I, Weiss G, Swinkels DW, Tjalsma H, Maggiorini M, Krayenbühl P, Rau M, Wojtal K, Müllhaupt B, Fried M, Gassmann M, Lutz T, Geier A. Adaptation of iron transport and matobolist to acute high altitude hypoxia in mountaineers. Hepatology 2013 Jun 20.
  19. Cippà PE, Krayenbühl PA. Increased height in HFE hemochromatosis. N Engl J Med 2013; 369(8):785-6. (original research results presented in a letter to the editor)
  20. Cippà PE, Boucsein I, Adams H, Krayenbühl PA. Estimating iron overload in patient’s with suspected liver disease and elevated serum ferritin. Am J Med. 2014; 127(10):1011.
  21. Muskalla AM, Suter PM, Saur M, Nowak A, Hersberger M, Krayenbühl PA. G-protein receptor kinase 4 polymorhhism and response to antihypertensive therapy. Clin Chem 2014; 60(12):1543-8.
  22. Stähli BE, Yonekawa K, Altwegg LA, Wyss C, Hof D, Fischbacher P, Brauchlin A, Schulthess G, Krayenbühl PA, von Eckardstein A, Hersberger M, Neidhart M, Gay S, Novopashenny I, Wolters R, Frank M, Wischnewsky MB, Lüscher TF, Maier W. Clinical criteria replenish high-sensitive troponin and inflammatory markers in the stratification of patients with suspected acute coronary syndrome. PloS One. 2014; 9(6):e98626.
  23. Reidt S, Nambar M, Serra A, Krayenbühl PA, Gruner C, Keller DI, Lüscher TF, Schied C. Disease progress in patients wirth Morbus Fabry after switching from  agalsidase beta to adalsidase alpha. Intern Med J 2014; 44(2):205-7.
  24. Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Büning C, Howaldt S, Stallmach A; AEGIS Study Grpoup. Ferric maltol is effective in correcting iron deficiency abemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015; 21(3):579-88.
  25. Nowak A, Artunc F, Serra AL, Pollock E, Krayenbühl PA, Müller C, Friedrich B. Sclerostin quo vadis? – is this a useful long-term morality parameter in prevalent hemodialysis patients? Kidney Blood Press Res 2015; 40(3):266-76.
  26. Barbey F, Joly D, Noel E, Drouineau O, Krayenbühl PA, Lidove O. Fabry disease in a geriatric population. Clin Genet 2015; 88(5):499-501.


  1. Krayenbuehl PA, Wiesli P, Meier T, Schulthess G. Effect of macrolides on peripheral arterial disease depends on patient selection and adequate treatment. Eur J Vasc Endovasc Surg 2005;30:334-5.
  2. Schmid C, Krayenbühl P, Wiesli P. Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes. Diabetologia 2009;52:2668-9.
  3. Burkhart A, Krayenbühl P, Suter P.Vitamin-B12 deficiency. Praxis (Bern 1994). 2010;99(7):411-412.
  4. Krayenbuehl PA, Heinrich H. One iron pill a day keeps fatigue away? Evid Based Med. 2012 Nov 17.

Case reports

  1. Krayenbuehl PA, Christen ST. Tricyclic Antidepressant Overdose Mimicking Myocardial Infarction. J Clin Basic Cardiol 2002; 5:197.
  2. van der Hoef M, Capaul R, Krayenbuhl P, Steurer-Stey C, Schulthess G. Insidious aspects of small pulmonary coin lesions. Praxis;92:1087-91.
  3. Vilan A, Furrer J, Krayenbuhl P, Schulthess G. Emergency landing due to a passenger with chest pain, dyspnea, and vomiting. Praxis 2004;93:1150-3.
  4. Grob U, Lachat M, Pfammatter T, Krayenbuhl P, Kaser L, Schulthess G. Subacute thoracic pain. Praxis 2004;93:1197-201.
  5. Meyer-Heim T, Krayenbuehl PA, Widmer U. Sore throat, arthralgia, fever and rash. Praxis 2006;6:275-55.
  6. Schultze D, Mani B, Dollenmair G, Sahli R, Zbinden A, Krayenbühl PA. Acute Hepatitis E Virus infection with coincident reactivation of Epstein-Barr virus infection in an immunosuppressed patient with rheumatoid arthritis: a case report. BMC Infect Dis. 2015; 15:474.


  1. Kolyvanos NU, Krayenbuhl PA, Kaser L, Vetter W. Microcytosis/microcytic anemia. Main symptoms: unspecific anemia, symptoms of basic diseases. Praxis 2005;94:1191-7.
  2. Krayenbuhl PA, Naumann KU, Kaser L, Vetter W. Acute intermittent porphyria. Praxis 2006;95:701-7. 2. Naumann UK, Krayenbuhl PA, Schulthess G, Kaser L, Vetter W. Infectious mononucleosis (primary infection with Epstein-Barr virus). Praxis 2006;95:525-31.
  3. Naumann UK, Krayenbuhl PA, Steurer-Stey C, Kaser L, Vetter W. Churg-Strauss syndrome. Main symptoms: asthma, eosinophilia, vasculitis symptoms (especially mononeuritis multiplex). Praxis 2006;95:2003-10.
  4. Naumann UK, Krayenbuhl PA, Kaser L, Vetter W. Chronic peri-aortitis: retroperitoneal fibrosis (Ormond disease), inflammatory abdominal aortic aneurysm and peri-aneurysmic retroperitoneal fibrosis. Praxis 2007;96:271-7.
  5. Krayenbuehl PA, Naumann KU, Käser L, Vetter W. Iron deficiency anemia in adults. Main symptoms: fatigue, pallor, (stress-) dyspnea, headache, concentration disorders. Praxis 2007;96:1241-7.
  6. Krayenbühl P, Naumann UK, Käser L, Vetter W. Hemochromatosis (hereditary, „primary“ hemochromatosis). Praxis 2007;96:2029-35.
  7. Kohler S, Schmid C, Krayenbühl PA. Hypercalcemia. Praxis 2009;98:233-40.
  8. Baumann K, Krayenbühl P. Fatigue. Praxis 2009;98:465-71.
  9. Andres M, Krayenbühl PA, Schwarz U. Differential involuntary muscle movement diagnosis. Praxis 2009;98:985-94.
  10. Fehr J, Favrat B, Schleiffenbaum B, Krayenbühl PA, Kapanci C, von Orelli F. Diagnosis and treatment of iron deficiency without anaemia. Praxis 2009;98:1445-51.
  11. Burkhart A, Krayenbühl P, Suter P.Vitamin B 12 deficiency. Praxis 2010;99:5-11.
  12. Krayenbühl P. Erhöhte Serumferritinwerte: Ursachen und Differentialdiagnose. HAUSARZT PRAXIS 2011;9;4-5.
  13. Krayenbühl P. Eisenmangel ohne Anämie: Realität oder Utopie. HAUSARZT PRAXIS 2011; 10-11;40-42.
  14. Haller S, Krayenbühl P, Gubler C. Blut ab ano. Praxis 2012;101(1):3-11.
  15. Krayenbühl P. Eisenstoffwechsel bei rheumatischen Entzündungsanämien. Rheuma-Schweiz 2012;1:22-25
  16. Franzen D, Krayenbühl PA, Lidove O, Aubert JD, Barbey F. Pulmonary involvement in Fabry clisease: Overview and perspectives. Eur J Intern Med. 2013; 24(8):707-13.
  17. Heinrich H, Kullak-Ublick GA, Krayenbühl PA. Living donor liver donation – primum nihil nocere? Praxis (Bern 1994). 2013; 102(21):1277-83.
  18. Krayenbühl PA.Eisenmangel ohne Anämie – Wissenswertes für den Hausarzt. Leading Opinion 2013, Ausgabe 1/13, Seite 80-83.
  19. Franzen D, Krayenbühl PA, Lidove O, Aubert JD, Barbey F. Pulmonary involvement in Fabry disease: overview and perspectives. Eur J Intern Med. 2013; 24(8):707-13.
  20. Schweizer S, Krayenbühl PA. The Birt-Hogg-Dube Syndrome. Praxis (Bern 1994). 2014; 103(23):1359-66.